Literature DB >> 9570234

Accidental transmission of HCV and treatment with interferon.

H Takagi1, M Uehara, S Kakizaki, H Takahashi, J Takezawa, K Kabeya, K Satoh, A Kojima, S Saito, T Matsumoto, Y Hashimoto, T Abe, T Yamada, K Konaka, R Shimoda, H Takayama, K Takehara, T Nagamine, M Mori.   

Abstract

Accidental transmission of contagious pathogens, especially hepatitis C virus (HCV), by needlestick or other means as an occupational hazard for medical staff is of concern. We retrospectively analysed cases of work-related accidental injury with pathogens such as hepatitis B virus (HBV), HCV, syphilis and human immunodeficiency virus (HIV) reported to the centres for disease control at 15 hospitals (total 5776 beds) in the Gunma prefecture, Japan, from December 1990 to August 1993 (24.7 months). There were 416 such cases (16.8 cases/month), with an incidence of 0.2-3.5 accidents per month per hospital. Such accidents occurred in 297 (71.2%) nurses, 98 (23.5%) medical doctors, 13 (3%) laboratory technicians, four (1.0%) hospital maintenance workers, one (0.2%) assistant nurse, one secretary and two others. There were 323 (77.6%) injuries caused by needlestick, 42 (10.1%) from suture needles or surgical knife cuts, 17 (4.1%) from blood splatters from patients into the eyes or mouth, 10 (2.4%) from contact with injured skin and 24 (5.8%) simple skin contacts. Of the pathogens, 60.3% were HCV, 22.6% HBV, 5.8% syphilis, 0.7% HIV and 10.6% were of unknown origin. Four cases (1.6%) of HCV infection were found and treated with one or two courses of interferon therapy, and HCV was subsequently cleared. All four patients were cured with interferon therapy. None of the HBV-injured cases resulted in infection, possibly because of prophylaxis with HB immunoglobulin and HB vaccine. No HIV or syphilis infection was contracted. In summary, chronic HCV infection acquired as an occupational hazard can be cured by appropriate treatment, such as with interferon, after early detection of the infection.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9570234     DOI: 10.1111/j.1440-1746.1998.01564.x

Source DB:  PubMed          Journal:  J Gastroenterol Hepatol        ISSN: 0815-9319            Impact factor:   4.029


  7 in total

1.  Hepatitis A, B, and C.

Authors:  R Gilson; M G Brook
Journal:  Sex Transm Infect       Date:  2006-12       Impact factor: 3.519

Review 2.  Managing occupational risks for hepatitis C transmission in the health care setting.

Authors:  David K Henderson
Journal:  Clin Microbiol Rev       Date:  2003-07       Impact factor: 26.132

Review 3.  Hepatitis C Virus Postexposure Prophylaxis in the Healthcare Worker: Why Direct-Acting Antivirals Don't Change a Thing.

Authors:  Susanna Naggie; David P Holland; Mark S Sulkowski; David L Thomas
Journal:  Clin Infect Dis       Date:  2016-09-28       Impact factor: 9.079

4.  Use of the minimum spanning tree model for molecular epidemiological investigation of a nosocomial outbreak of hepatitis C virus infection.

Authors:  Enea Spada; Luciano Sagliocca; John Sourdis; Anna Rosa Garbuglia; Vincenzo Poggi; Carmela De Fusco; Alfonso Mele
Journal:  J Clin Microbiol       Date:  2004-09       Impact factor: 5.948

Review 5.  [Injuries from needles contaminated with hepatitis C virus: how high is the risk of seroconversion for medical personnel really?].

Authors:  A Kubitschke; C Bader; H L Tillmann; M P Manns; S Kuhn; H Wedemeyer
Journal:  Internist (Berl)       Date:  2007-10       Impact factor: 0.743

6.  Pilot study of postexposure prophylaxis for hepatitis C virus in healthcare workers.

Authors:  Kathleen E Corey; Julie C Servoss; Deborah R Casson; Arthur Y Kim; Gregory K Robbins; Jean Franzini; Katherine Twitchell; Susan C Loomis; Diane R Abraczinskas; Adam M Terella; Jules L Dienstag; Raymond T Chung
Journal:  Infect Control Hosp Epidemiol       Date:  2009-10       Impact factor: 3.254

7.  Costs and cost-effectiveness of different follow-up schedules for detection of occupational hepatitis C virus infection.

Authors:  S Deuffic-Burban; D Abiteboul; F Lot; M Branger; E Bouvet; Y Yazdanpanah
Journal:  Gut       Date:  2008-09-29       Impact factor: 23.059

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.